Calvin Ho to Treatment Outcome
This is a "connection" page, showing publications Calvin Ho has written about Treatment Outcome.
Connection Strength
0.193
-
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. 2026 Jun; 32(6):2017-2025.
Score: 0.052
-
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2025 Nov; 84(11):1888-1899.
Score: 0.050
-
Benralizumab does not elicit therapeutic effect in patients?with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J Dermatol. 2024 Jul 16; 191(2):187-199.
Score: 0.046
-
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary. Immunotherapy. 2024; 16(10):641-648.
Score: 0.045